WHAT IS CLAIMED IS:

1. A solid pharmaceutical composition comprising 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid (Compound A) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable meltable binder, wherein the weight ratio of Compound A or a pharmaceutically acceptable salt thereof to the pharmaceutically acceptable meltable binder is from about 1:1 to about 15:1.

2. The solid pharmaceutical composition of claim 1, wherein the weight ratio of Compound A or a pharmaceutically acceptable salt thereof to the pharmaceutically acceptable meltable binder is from about 3:1 to about 12:1.

~~2.~~**3.** The solid pharmaceutical composition of claim 1 or 2, wherein the pharmaceutically acceptable meltable binder is selected from the group consisting of polyethylene glycol, hydroxypropylcellulose, d-α tocopheryl polyethylene glycol 1000 succinate and poloxamer.

~~3.~~**4.** The solid pharmaceutical composition of claim 1 or 2, wherein the pharmaceutically acceptable meltable binder is miscible with 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid (Compound A) or a pharmaceutically acceptable salt thereof.

~~4.~~**5.** The solid pharmaceutical composition of any one of the preceding claims, wherein the pharmaceutically acceptable meltable binder is present in an amount from about 0.5% by weight to about 20% by weight of the solid pharmaceutical composition, preferably from about 2% by weight to about 10% by weight of the solid pharmaceutical composition.

~~5.~~**6.** The solid pharmaceutical composition of any one of the preceding claims, wherein the solid pharmaceutical composition further comprises a disintegrant;~~.~~

~~**6.** The solid pharmaceutical composition of claim **5**,~~ optionally wherein the disintegrant is selected from the group consisting of cross-linked modified starches, cross-linked polyvinylpyrrolidone, and cross-linked carboxymethyl cellulose~~,~~ and/or

~~**7.** The solid pharmaceutical composition of claim **5** or claim **6**,~~ optionally wherein the disintegrant is present in an amount from about 2% by weight to about 30% by weight of the solid pharmaceutical composition, preferably from about 3% to about 10% by weight of the solid pharmaceutical composition, more preferably from about 4% by weight to about 6% by weight of the solid pharmaceutical composition.

~~**8.**~~**7.** The solid pharmaceutical composition of claim **1**, wherein the solid pharmaceutical composition further comprises a glidant~~;~~

~~**9.** The solid pharmaceutical composition of claim **8**,~~ optionally wherein the glidant is colloidal silicon dioxide~~,~~ and/or

~~**10.** The solid pharmaceutical composition of claim **8** or claim **9**,~~ optionally wherein the glidant is present in an amount from about 0.1% by weight to about 5% by weight of the solid pharmaceutical composition, preferably from about 0.2% by weight to about 3% by weight of the solid pharmaceutical composition.

~~**11.**~~**8.** The solid pharmaceutical composition of claim **1**, wherein the solid pharmaceutical composition further comprises a pH modifying agent~~;~~

~~**12.** The solid pharmaceutical composition of claim **11**,~~ optionally wherein the pH modifying agent is an alkaline or alkaline earth metal hydroxide, or a weak base with pKa 6, or a polymeric base, a cationic resin, or an alkaline or alkaline earth metal salt, preferably sodium carbonate, and/or~~.~~

~~**13.** The solid pharmaceutical composition of claim **11** or claim **12**,~~ optionally wherein weight weight ratio of Compound A, or salt thereof to the pH modifying agent is from about 1:1 to about 10:1, such as from about 2:1 to about 10:1 or from about 2:1 to about 8:1, or from about 2:1 to about 6:1, or from about 2:1 to about 4:1, or from about 2:1 to about 1:1.

~~14.~~9. The solid pharmaceutical composition of any one of the preceding claims, wherein Compound A or the pharmaceutically acceptable salt thereof is present in an amount from about 40% by weight to about 80% by weight of the solid pharmaceutical composition, preferably in an amount from about 50% by weight to about 70% by weight of the solid pharmaceutical composition;

~~15. The solid pharmaceutical composition of any one of the preceding claims,~~ optionally wherein the solid pharmaceutical composition releases at least about 80% of Compound A or the pharmaceutically acceptable salt thereof in about 60 minutes, measured using USP apparatus II in 900 mL of sodium phosphate, pH 6.8, at 37 °C and paddle speed of 50 rpm.

~~16. The solid pharmaceutical composition of any one of the preceding claims, wherein the pharmaceutical composition comprises a salt of Compound A.~~

~~17. The solid pharmaceutical composition of claim 16, wherein the salt of Compound A is sodium 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)butanoate.~~

~~18. The solid pharmaceutical composition of claim 16, wherein the salt of Compound A is amorphous sodium 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)butanoate~~.

~~19.~~10. The~~A~~ solid pharmaceutical composition of claim 1comprising about 200 mg or 300 mg of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid (Compound A) or a pharmaceutically acceptable salt thereof; and polyethylene glycol, wherein the polyethylene glycol is present in the solid pharmaceutical composition in an amount from about 2% to about 20%, optionally wherein the polyethylene glycol is polyethylene glycol 3350;~~.~~

~~20. A solid pharmaceutical composition comprising about 300 mg of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid (Compound A) or a~~

~~pharmaceutically acceptable salt thereof; and polyethylene glycol, wherein the polyethylene glycol is present in the solid pharmaceutical composition in an amount from about 2% to about 20%.~~

~~**21.** The pharmaceutical composition of claim **19** or claim **20**, wherein the polyethylene glycol is polyethylene glycol 3350.~~

~~**22.** The pharmaceutical composition of any one of claims **19-21**,~~ optionally wherein the pharmaceutical composition further compris~~es~~~~ing~~ a pH modifying agent~~.~~;

~~**23.** The pharmaceutical composition of claim **22**,~~ optionally wherein the pH modifying agent is an alkaline or alkaline earth metal hydroxide or an alkaline or alkaline earth metal salt, preferably sodium carbonate.

~~**24.** The pharmaceutical composition of any one of claims **19-23**, wherein the pharmaceutical composition comprises a salt of Compound A.~~

~~**25.** The pharmaceutical composition of claim **24**, wherein the salt of Compound A is sodium 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)butanoate.~~

~~**26.** The pharmaceutical composition of claim **24**, wherein the salt of Compound A is amorphous sodium 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)butanoate.~~

~~**27.**~~**11.** The~~A~~ solid pharmaceutical composition of claim 1, the composition comprising:

4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-di oxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid (Compound A) or a pharmaceutically acceptable salt thereof and ~~a~~the pharmaceutically acceptable meltable binder in a solid matrix, such as amorphous solid dispersion;

a pH modifying agent;

a disintegrant; and

a glidant;

wherein the pH modifying agent, the disintegrant, and the glidant are outside the solid dispersion.

~~28.~~12. The solid pharmaceutical composition of claim 11~~27~~, wherein the pharmaceutically acceptable meltable binder is selected from the group consisting of polyethylene glycol 3350, hydroxypropylcellulose, and poloxamer 188~~;~~ and/or

~~29. The solid pharmaceutical composition of claim 27 or claim 28,~~ wherein the pharmaceutically acceptable meltable binder is present in an amount from about 1% by weight to about 20% by weight of the solid pharmaceutical composition, preferably from about 2% by weight to about 10% by weight of the solid pharmaceutical composition~~;~~ and/or

~~30. The solid pharmaceutical composition of claim 27,~~ wherein the disintegrant is selected from the group consisting of cross-linked modified starches, cross-linked polyvinylpyrrolidone, and cross-linked carboxymethyl cellulose~~.~~,

~~31. The solid pharmaceutical composition of any one of claims 27-30,~~ optionally wherein the disintegrant is present in an amount from about 2% by weight to about 10% by weight of the solid pharmaceutical composition, preferably from about 3% by weight to about 6% by weight of the solid pharmaceutical composition; and/or~~.~~

~~32. The solid pharmaceutical composition of claim 27,~~ wherein the glidant is colloidal silicon dioxide~~.~~

~~33. The solid pharmaceutical composition of any one of claims 27-32~~, optionally wherein the glidant is present in an amount from about 0.1% by weight to about 5% by weight of the solid pharmaceutical composition, preferably from about 1% by weight to about 3% by weight of the solid pharmaceutical composition; and/or~~.~~

~~34. The solid pharmaceutical composition of claim 27,~~ wherein the solid pharmaceutical composition further comprises a pH modifying agent~~.~~

~~35. The solid pharmaceutical composition of claim 34~~, optionally wherein the pH modifying agent is an alkaline or alkaline earth metal hydroxide or an alkaline or alkaline earth metal salt, preferably sodium carbonate and/or~~.~~

~~36.~~ ~~The solid pharmaceutical composition of claim 34 or claim 35~~, optionally wherein weight ratio of the compound A, or salt thereof to the pH modifying agent is from about 1:1 to about 10:1, such as from about 2:1 to about 10:1 or from about 2:1 to about 8:1, or from about 2:1 to about 6:1, or from about 2:1 to about 4:1, or from about 2:1 to about 1:1~~.~~.

~~37.~~13. The pharmaceutical composition of any preceding claim~~one of claims 27-36~~, wherein the pharmaceutical composition comprises a salt of Compound A;~~.~~

~~38.~~ ~~The pharmaceutical composition of claim 37,~~ optionally wherein the salt of Compound A is sodium 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)butanoate;~~.~~

~~39.~~ ~~The pharmaceutical composition of claim 37,~~ optionally wherein the salt of Compound A is amorphous sodium 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-di oxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)butanoate.

~~40.~~14. A solid pharmaceutical composition according to claim 1, the composition comprising:

(a) from about 55% to about 60% by weight of amorphous sodium 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)butanoate;
(b) from about 4% to about 6% by weight of a pharmaceutically acceptable hydrophilic meltable polymer;
(c) from about 25% to about 35% by weight of a pH modifying agent;
(d) from about 4% to about 6% by weight of a disintegrant;
(e) from about 0.1% to about 2% by weight of a glidant; and
(f) from about 0.5% to about 1.5% by weight of a lubricant.

~~41.~~15. The solid pharmaceutical composition of claim 14~~40~~, wherein the pharmaceutically acceptable hydrophilic meltable polymer is polyethylene glycol, preferably polyethylene glycol 3350; and/or~~.~~

~~42.~~ ~~The solid pharmaceutical composition of claim 40 or claim 41,~~ wherein the pH modifying agent is sodium carbonate, preferably sodium carbonate monohydrate; and/or~~.~~

~~43.~~ ~~The solid pharmaceutical composition of any one of claims 40-42,~~ wherein the disintegrant is crospovidone; and/or~~.~~

~~44.~~ ~~The solid pharmaceutical composition of any one of claims 40-43,~~ wherein the glidant is colloidal silicon dioxide; and/or~~.~~

~~45.~~ ~~The solid pharmaceutical composition of any one of claims 40-44,~~ wherein the lubricant is magnesium stearate.

~~46.~~16. Use of the solid pharmaceutical composition of any one of claims 1-15 in the manufacture of a medicament for~~A method of~~ treating endometriosis, ~~the method comprising administering~~ wherein the solid pharmaceutical composition of any one of claims 1-15~~45~~ is to be administered to a patient in need thereof.

~~47.~~17. Use of the solid pharmaceutical composition of any one of claims 1-15 in the manufacture of a medicament for~~A method of~~ treating uterine fibroids, ~~the method comprising administering~~ wherein the solid pharmaceutical composition of any one of claims 1-15~~45~~ is to be administered to a patient in need thereof.

~~48.~~18. Use of the solid pharmaceutical composition of any one of claims 1-15~~A method~~ in the manufacture of a medicament ~~-~~for providing partial to substantially full suppression of estradiol in the treatment of a female patient with endometriosis or uterine fibroids,~~ the method comprising administering~~wherein~~-~~ the solid pharmaceutical composition of any one of claims 1-15~~45~~ is to be administered to the patient~~.~~;

~~49.~~ ~~The method of claim 48,~~ optionally wherein estradiol levels in the female patient are less than about 50 pg/mL;~~.~~

~~50.~~ ~~The method of claim 48,~~ optionally wherein estradiol levels in the female patient are less than about 20 pg/mL.

~~51.~~19. Use of the solid pharmaceutical composition of any one of claims 1-15 in the manufacture of a medicament~~A method of~~ for treating non-dominant adenomyosis or symptomatic adenomyosis, wherein ~~the method comprising administering~~ the pharmaceutical composition of claims 1-15~~45~~ is to be administered to a patient in need thereof;~~.~~

~~52.~~ ~~The method of claim 51,~~ optionally wherein Compound A is dosed 300 mg twice-a-day or 600 mg once-a-day.

~~53. The method of claim 51, wherein the non-dominant adenomyosis or symptomatic adenomyosis treatment comprises:~~

~~(a) Reduction in heavy menstrual bleeding to < 80 ml/mo with a > 50% reduction from baseline in menstrual blood loss (MBL) at Month 6;~~

~~(b) A clinically meaningful decrease (defined as > 30% reduction from baseline) in pelvic pain at Month 3;~~

~~(c) Reduction in heavy menstrual bleeding to < 80 ml/mo with a > 50% reduction from baseline in MBL at Month 3;~~

~~(d) Reduction in heavy menstrual bleeding to < 80 ml/mo with a > 50% reduction from baseline in MBL at Month 12;~~

~~(e) A clinically meaningful decrease (defined as > 30% reduction) from baseline in pelvic pain at Month 6;~~

~~(f) MBL volume mean reduction from baseline vs placebo;~~

~~(g) Suppression of bleeding as defined by amenorrhea +/- spotting;~~

~~(h) Suppression of menstrual cramps that last throughout the menstrual period;~~

~~(i) Reduction of pain during intercourse; or~~

~~(j) Reduction of blood clots that pass during menstrual period.~~

~~54.~~20. Use of a solid pharmaceutical composition in the manufacture of a medicament for~~A method of~~ treating heavy menstrual bleeding and pelvic pain in a woman with symptomatic

adenomyosis~~s comprising administering~~, wherein a pharmaceutical composition comprising about 300 mg equivalent of Compound A is to be administered, wherein said composition includes:

(g) about 33.2% by weight of sodium 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)butanoate;

(h) about 16.7% by weight of an alkali metal salt; and

(i) about 51.1% by weight of one or more excipients, wherein the excipients comprises a binder, a water soluble filler, a lubricant, and a film-coating.

~~**55.** The method of claim **54,**~~ optionally said composition comprising:

(a) about 33.2% by weight of sodium 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)butanoate;

(b) about 2.9% by weight of a binder;

(c) about 16.7% by weight of an alkali metal salt;

(d) about 41.6% by weight of a water soluble filler;

(e) about 1.8% by weight of a lubricant; and

(f) about 3.8% by weight of a film-coating; and/or~~.~~

~~**56.** The method of of claim **54,**~~ optionally wherein the treatment further compri~~s~~ses~~sing~~ an add-back therapy selected from a group consisting of estradiol, norethindrone acetate, or combinations thereof.~~.~~

~~**57.** The method of claim **56,**~~ optionally wherein the add-back therapy comprises 1 mg estradiol, 0.5 mg of norethindrone acetate, or combinations thereof and wherein the add-back therapy is to be administered ~~-~~once-a-day, to patients in need thereof.

~~**58.** The method of claim **54**, wherein the symptomatic adenomyosis treatment comprises:~~

~~(a) Reduction in heavy menstrual bleeding to < 80 ml/mo with a > 50% reduction from baseline in menstrual blood loss (MBL) at Month 6;~~

~~(b) A clinically meaningful decrease (defined as > 30% reduction from baseline) in pelvic pain at Month 3;~~

~~(c) Reduction in heavy menstrual bleeding to < 80 ml/mo with a > 50% reduction from baseline in MBL at Month 3;~~

~~(d) Reduction in heavy menstrual bleeding to < 80 ml/mo with a > 50% reduction from baseline in MBL at Month 12;~~

~~(e) A clinically meaningful decrease (defined as > 30% reduction) from baseline in pelvic pain at Month 6;~~

~~(f) MBL volume mean reduction from baseline vs placebo;~~

~~(g) Suppression of bleeding as defined by amenorrhea +/- spotting;~~

~~(h) Suppression of menstrual cramps that last throughout the menstrual period;~~

~~(i) Reduction of pain during intercourse; or~~

~~(j) Reduction of blood clots that pass during menstrual period.~~

~~59.~~21. Use of a solid pharmaceutical composition in the manufacture of a medicament~~A method of~~for treating heavy menstrual bleeding and pelvic pain in a woman with non-dominant adenomyosis ~~comprising administering~~, wherein a pharmaceutical composition comprising about 300 mg equivalent of Compound A is to be administered, wherein said composition includes:

a) about 33.2% by weight of sodium 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)butanoate;

b) about 16.7% by weight of an alkali metal salt; and

c) about 51.1% by weight of one or more excipients, wherein the excipients comprises a binder, a water soluble filler, a lubricant, and a film-coating;~~.~~

~~**d)** The method of claim 85,~~ optionally said composition comprising:

~~**e)**~~**a)** about 33.2% by weight of sodium 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)butanoate;

~~**f)**~~**b)** about 2.9% by weight of a binder;

~~g)~~c) about 16.7% by weight of an alkali metal salt;

~~h)~~d) about 41.6% by weight of a water soluble filler;

~~i)~~e) about 1.8% by weight of a lubricant; and

~~j)~~f) about 3.8% by weight of a film-coating; and/or~~.~~

~~60.~~ ~~The method of of claim 59,~~ optionally wherein the treatment further comprising an add-back therapy selected from a group consisting of estradiol, norethindrone acetate, or combinations thereof~~,~~ ~~.~~

~~61.~~ ~~The method of claim 59,~~ optionally wherein the add-back therapy comprises 1 mg estradiol, 0.5 mg of norethindrone acetate, or combinations thereof and wherein the add-back therapy is administered ~~-~~once-a-day, to patients in need thereof.

~~62.~~22. The use~~method~~ of any of claims 19-21~~59~~, wherein the non-dominant adenomyosis or symptomatic adenomyosis treatment comprises:

(a) Reduction in heavy menstrual bleeding to < 80 ml/mo with a > 50% reduction from baseline in menstrual blood loss (MBL) at Month 6;

(b) A clinically meaningful decrease (defined as > 30% reduction from baseline) in pelvic pain at Month 3;

(c) Reduction in heavy menstrual bleeding to < 80 ml/mo with a > 50% reduction from baseline in MBL at Month 3;

(d) Reduction in heavy menstrual bleeding to < 80 ml/mo with a > 50% reduction from baseline in MBL at Month 12;

(e) A clinically meaningful decrease (defined as > 30% reduction) from baseline in pelvic pain at Month 6;

(f) MBL volume mean reduction from baseline vs placebo;

(g) Suppression of bleeding as defined by amenorrhea +/- spotting;

(h) Suppression of menstrual cramps that last throughout the menstrual period;

(i) Reduction of pain during intercourse; or

(j) Reduction of blood clots that pass during menstrual period.

23. The solid pharmaceutical composition of any one of claims 1-15 for use in therapy.